Development of NAFLD ‐Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation
Cell Proliferation · 2026-04 · 59 (4)
DOI: 10.1111/cpr.70118 ↗At a glance
Journal article in Cell Proliferation, published online on 2025-08-27. Written by Xiao-Yan You and 3 co-authors. Institution: Henan Engineering Research Center of Food Microbiology, College of Food and Bioengineering, Henan University of Science and Technology, Luoyang, Chin…. Major MEDLINE topics: Non-alcoholic Fatty Liver Disease, Glucagon-Like Peptides, Organoids, Liver. Cited 5 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY 4.0). Funded by: Strategic Priority Research Program of the Chinese Academy of Sciences, Major Project of Haihe Laboratory of Synthetic Biology, Tianjin Synthetic Biotechnology Innovation Capacity Improvement Projects.
Abstract (original language)
Progressive non‐alcoholic fatty liver disease (NAFLD) may culminate in severe complications, including fibrosis, cirrhosis and hepatocellular carcinoma, yet therapeutic breakthroughs remain elusive, necessitating novel pharmacological strategies. Semaglutide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist clinically approved for type 2 diabetes and obesity management, has demonstrated pleiotropic effects in preclinical NAFLD models. In this study, we investigated semaglutide's therapeutic efficacy and mechanisms in a human liver organoids (hLOs) model of NAFLD. Utilising microengineered array chips, human induced pluripotent stem cells (hiPSCs) were differentiated into hLOs with functional hepatic properties. NAFLD pathology was induced via free fatty acid (FFA) exposure, recapitulating disease hallmarks such as steatosis, inflammatory cytokine elevation and fibrogenic activation. Semaglutide treatment at 50 nM significantly attenuated lipid deposition caused by FFAs and reduced triglyceride levels by 8‐fold and cholesterol levels by 1.8‐fold. It also inhibited the expression of pro‐inflammatory markers (IL‐6, IL‐8, TNF‐α) by about 1.5–2 fold and increased the level of lipolytic genes by about 45%. These findings elucidate the therapeutic potential of semaglutide in attenuating key NAFLD‐associated pathologies and establish a robust in vitro platform for preclinical drug evaluation. The study provides critical insights into targeted NAFLD interventions and supports the translation of GLP‐1‐based therapies into clinical practice, addressing an unmet need in hepatology.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Henan Engineering Research Center of Food Microbiology, College of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China.
- Master Lab for Innovative Application of Nature Products, National Center of Technology Innovation for Synthetic Biology, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences (CAS), Tianjin, China.
- Haihe Laboratory of Synthetic Biology, Tianjin, China.
- School of Life Sciences, Faculty of Medicine, Tianjin Key Laboratory of Function and Application of Biological Macromolecular Structures, Tianjin University, Tianjin, China.
- CAS-Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences, Institute of Plant Physiology and Ecology, Chinese Academy of Sciences, Shanghai, China.
- CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
Funding
- Strategic Priority Research Program of the Chinese Academy of Sciences
- Major Project of Haihe Laboratory of Synthetic Biology
- Tianjin Synthetic Biotechnology Innovation Capacity Improvement Projects
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
Cite
APA
You, X. Y., Li, X. Y., Wang, H., & Zhao, G. P. (2026). Development of NAFLD ‐Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation. Cell Proliferation, 59(4). https://doi.org/10.1111/cpr.70118
Vancouver
You XY, Li XY, Wang H, Zhao GP. Development of NAFLD ‐Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation. Cell Proliferation. 2026;59(4). doi:10.1111/cpr.70118
BibTeX
@article{You2026,
author = {You, Xiao-Yan and Li, Xiang-Yang and Wang, Hui and Zhao, Guo-Ping},
title = {Development of NAFLD ‐Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation},
journal = {Cell Proliferation},
year = {2026},
volume = {59},
number = {4},
doi = {10.1111/cpr.70118}
}
EUVIMED